Satsuma Pharmaceuticals to to participate in the following November Virtual Investor Conferences
Satsuma Pharmaceuticals (Nasdaq: STSA) announced its participation in two upcoming virtual healthcare conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Satsuma Pharmaceuticals (Nasdaq: STSA) announced its participation in two upcoming virtual healthcare conferences. The Credit Suisse 29th Annual Healthcare Conference will take place from November 9-12, 2020, featuring one-on-one meetings with management. Following this, Satsuma will attend the Stifel 2020 Virtual Healthcare Conference from November 16-18, 2020, also involving one-on-one management meetings. Satsuma focuses on developing STS101, a novel migraine treatment utilizing a proprietary nasal delivery device for rapid self-administration.
Details
News Market Reaction – STSA
The recorded move for STSA in the trading session of this news was +3.05%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Credit Suisse - 29th Annual Healthcare Conference -
November 9th -12th
- Stifel 2020 Virtual Healthcare Conference -
November 16th -18th
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA) a clinical-stage biopharmaceutical company, today announced that management will participate in the following conferences in the month of November. Please see additional details below:
| Credit Suisse 29th Annual Healthcare Conference | |
| Dates: | Monday – Thursday, November 9th-12th 2020 |
| Format: | One-on-One meetings with Satsuma Management |
| Location: | Virtual Meetings |
| Stifel 2020 Virtual Healthcare Conference | |
| Date: | Monday – Wednesday, November 16th-18th 2020 |
| Format: | One-on-One meetings with Satsuma Management |
| Location: | Virtual Meetings |
About Satsuma Pharmaceuticals and STS101
Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic product for the acute treatment of migraine, STS101. STS101 is a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate (DHE), which can be quickly and easily self-administered with a proprietary pre-filled, single-use, nasal delivery device. In developing STS101, Satsuma has applied proprietary nasal drug delivery, dry-powder formulation, and engineered drug particle technologies to create a compact, simple-to-use, non-injectable DHE product that can be rapidly self-administered in a matter of seconds.
Satsuma is headquartered in South San Francisco, California with operations in both California and Research Triangle Park, North Carolina. For further information, please visit www.satsumarx.com.
INVESTOR AND CORPORATE CONTACTS:
Corey Davis, PhD
LifeSci Advisors, LLC
cdavis@lifesciadvisors.com
Tom O’Neil, Chief Financial Officer
Satsuma Pharmaceuticals, Inc.
tom@satsumarx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.